Translational Drug Development (TD2)
Rachel Dukes has extensive experience in clinical data management and administration within the pharmaceutical and educational sectors. Currently serving as a Clinical Data Associate II at Translational Drug Development (TD2) since November 2020, Rachel previously held the position of Clinical Data Manager at ERT from May 2018 to November 2020. Rachel's career began at Bivona Child Advocacy Center as a Data Administrator, followed by roles at Destiny Christian School & Preschool as an Office Manager and at iCardiac as both an Associate Data Manager and Data Support Specialist. Rachel holds an education from Valor Christian College, where studies took place from 1996 to 1999.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.